预约演示
更新于：2025-12-29
Aflibercept
阿柏西普
更新于：2025-12-29
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2011-11-18), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、孤儿药 (美国)、优先审评 (中国)、优先审评 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 4715606
来源: *****
关联
517
项与 阿柏西普 相关的临床试验NCT07301775
A Randomised Controlled Trial Comparing Efficacy of Single Versus Multiple Intravitreal Anti-VEGF Injections to Prevent Diabetic Retinopathy Progression in Patients Undergoing Cataract Surgery
ChiCTR2500115109
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients with Polypoidal Choroidal Vasculopathy (PCV)
ChiCTR2500115643
A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants with Neovascular Age-Related Macular Degeneration – The STELLAR Trial
100 项与 阿柏西普 相关的临床结果
登录后查看更多信息
100 项与 阿柏西普 相关的转化医学
登录后查看更多信息
100 项与 阿柏西普 相关的专利（医药）
登录后查看更多信息
3,407
项与 阿柏西普 相关的文献（医药）2026-05-01Value in Health Regional Issues
Cost-Effectiveness of Vascular Endothelial Growth Factor Inhibitors in the Management of Wet Age-Related Macular Degeneration: A Systematic Review
Article
作者: Paneerselvam, Ganesh S ; Kenneth, Lee K C ; Wai, Ng J ; Sheng, Lim J
OBJECTIVES:
To evaluate the cost-effectiveness of VEGF inhibitors, ranibizumab, aflibercept, bevacizumab, brolucizumab, pegaptanib, and conbercept for wAMD treatment.
METHODS:
A systematic search was conducted in PubMed, Cochrane, and SpringerLink databases to identify cost-effectiveness analyses and cost-utility analyses related to wAMD treatment. Eligible studies were assessed using Drummond's 10-point checklist to evaluate methodological quality. The extracted data included intervention costs, quality-adjusted life-years, and incremental cost-effectiveness ratios.
RESULTS:
Twenty-two studies met the inclusion criteria. Bevacizumab and brolucizumab were frequently reported as cost-effective alternatives, offering comparable or superior visual outcomes at lower costs than ranibizumab or aflibercept. Pegaptanib was consistently less cost-effective. Findings for ranibizumab versus aflibercept varied by treatment regimen and analytic assumptions. Across studies, cost-effectiveness estimates were influenced by model perspective, time horizon, exclusion of adverse events, and single-eye modeling. A further limitation is that in contexts of non-inferior efficacy, small incremental quality-adjusted life-years differences may artificially inflate incremental cost-effectiveness ratios, potentially overstating the costs relative to benefits.
CONCLUSIONS:
Decision making in wAMD treatment requires more thorough economic evaluations that incorporate standardized methodologies and lengthy cost assessments.
2026-02-01CELLULAR SIGNALLING
siRASA1 in vascular endothelial cells alleviates subretinal fibrosis through inhibiting macrophage-myofibroblast transdifferentiation via SHH signaling pathway
Article
作者: Ma, Jingyang ; Wu, Yan ; Lin, Ruoyi ; Jiang, Lei ; Liang, Feng ; Hu, Chengyu ; Xu, Zihang ; Cai, Wenting ; Yu, Jing ; Luo, Yunhong
Subretinal fibrosis (SRF) is a vision-threatening complication of neovascular age-related macular degeneration (nAMD) driven by angiogenesis, inflammation, and collagen deposition，which is refractory to current anti-VEGF treatments. This study investigates the role of RASA1 in promoting SRF through Sonic Hedgehog (SHH) signaling. We found that VEGF stimulation upregulates RASA1 in human umbilical vein endothelial cells (HUVECs), potentiating the secretion of SHH. Secreted SHH then activates the SHH-SMO/PTCH1-GLI1 axis in macrophages, driving their transdifferentiation into myofibroblasts and promoting fibrogenesis. Furthermore, a positive feedback loop was identified: macrophage-derived EFNB2 activated EphB4-RASA1 in HUVECs, exacerbating fibrosis. To therapeutically disrupt this circuit, we engineered a multifunctional nanoparticle system, MGPDA@Eylea/siRASA1, for the co-delivery of siRASA1 and the anti-VEGF drug Eylea. This nanotherapeutic demonstrated excellent biocompatibility and effectively attenuated the fibrotic cascade by suppressing RASA1 expression, inhibiting SHH signaling, and mitigating macrophage-to-myofibroblast transition (MMT), thereby delaying SRF progression. Our work unveils a previously unrecognized intercellular circuit driving fibrosis and presents a promising nanomedicine-based strategy for managing fibrotic complications in nAMD.
2026-02-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Computational modeling of anti-VEGFA drug interactions with VEGF-A: Insights into therapeutic strategies for neovascular AMD
Article
作者: Román-Vallina, Alba ; Parra-Sánchez, Ángel ; Fernández, Eduardo ; Martínez-Navarrete, Gema
Vascular endothelial growth factor A (VEGF-A) is the main driver of pathological angiogenesis and represents the primary therapeutic target in neovascular age-related macular degeneration (nAMD). Several anti-VEGF agents are currently available, but systematic comparisons of their molecular interactions with VEGF-A remain limited. In this study, we performed the first integrated in silico evaluation of six clinically relevant anti-VEGF drugs: abicipar, aflibercept, bevacizumab, brolucizumab, faricimab, and ranibizumab. Structural modeling, residue conservation analysis, molecular docking (HADDOCK), and binding affinity prediction (PRODIGY) were employed to assess drug-VEGF-A interactions in terms of stability, energetic contributions, and key conserved residues. Our results showed that bevacizumab exhibited the most stable interaction profile, dominated by van der Waals forces and supported by highly conserved residues. Aflibercept displayed strong electrostatic stabilization, while ranibizumab and brolucizumab achieved robust interactions through mixed forces. Faricimab presented weaker binding stability but its dual-target mechanism, involving VEGF-A and angiopoietin-2, may extend its therapeutic efficacy beyond VEGF-A inhibition. Abicipar demonstrated favorable stability despite structural differences from conventional antibodies. Notably, hydrophobic interactions were consistently identified as a central determinant of complex stability across all drugs, whereas an excess of charged residues correlated with reduced affinity. This systematic analysis highlights the coexistence of evolutionary conservation and rational molecular engineering as complementary strategies shaping anti-VEGF drug performance. Overall, our findings demonstrate that computational modeling offers a cost-effective and predictive tool to guide the optimization of current therapies and the rational design of next-generation anti-VEGF agents for nAMD and other retinal vascular disorders.
1,359
项与 阿柏西普 相关的新闻（医药）2025-12-29
抗体药物偶联物临床2期上市批准临床1期
2025-12-27
100 项与 阿柏西普 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早产儿视网膜病变 | 日本 | 2022-09-26 | |
| 新生血管性青光眼 | 日本 | 2020-03-25 | |
| 结直肠癌 | 日本 | 2017-03-30 | |
| 视网膜静脉阻塞 | 日本 | 2015-06-26 | |
| 糖尿病性视网膜病变 | 美国 | 2015-03-25 | |
| 黄斑水肿 | 日本 | 2013-11-22 | |
| 失明 | 韩国 | 2013-03-20 | |
| 脉络膜新生血管 | 日本 | 2012-09-28 | |
| 年龄相关性黄斑变性1型 | 日本 | 2012-09-28 | |
| 转移性结直肠癌 | 美国 | 2012-08-03 | |
| 糖尿病性黄斑水肿 | 澳大利亚 | 2012-03-07 | |
| 近视脉络膜新生血管 | 澳大利亚 | 2012-03-07 | |
| 视网膜静脉阻塞相关黄斑水肿 | 澳大利亚 | 2012-03-07 | |
| 湿性年龄相关性黄斑变性 | 美国 | 2011-11-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 139 | Aflibercept 8 mg every 12 weeks | 遞鹹膚範遞鹹夢襯醖網(繭醖鹹遞願壓構觸蓋築) = 範築壓淵窪鹽蓋簾簾願 鬱廠鹽廠鑰醖鹽鏇艱鏇 (夢糧獵獵衊選齋廠襯鏇, 0.4) 更多 | 积极 | 2025-12-18 | ||
Aflibercept 8 mg every 16 weeks | 遞鹹膚範遞鹹夢襯醖網(繭醖鹹遞願壓構觸蓋築) = 繭觸願鑰製積醖窪窪願 鬱廠鹽廠鑰醖鹽鏇艱鏇 (夢糧獵獵衊選齋廠襯鏇, 0.5) 更多 | ||||||
临床3期 | 892 | (Aflibercept 2q4) | 構衊選鹽網獵構衊製顧(簾齋艱遞廠餘製簾鏇遞) = 襯範窪襯顧製築衊積蓋 願餘鏇蓋憲蓋願製窪艱 (淵築鹹築鹹齋壓膚鹽範, 0.7) 更多 | - | 2025-12-18 | ||
(Aflibercept 8q8/3) | 構衊選鹽網獵構衊製顧(簾齋艱遞廠餘製簾鏇遞) = 遞製淵鹹顧顧膚鑰鹽鏇 願餘鏇蓋憲蓋願製窪艱 (淵築鹹築鹹齋壓膚鹽範, 0.7) 更多 | ||||||
临床2期 | 128 | (Intravitreal aflibercept injection) | 範簾選遞簾鹽鬱壓觸膚 = 遞餘顧鑰鑰鹽選鹽衊壓 網願鏇淵觸獵積窪鑰餘 (壓鬱構廠壓築糧鬱餘簾, 廠鹹蓋觸觸憲製壓簾獵 ~ 壓膚襯膚積網廠夢繭簾) 更多 | - | 2025-11-14 | ||
Placebo (Placebo) | 範簾選遞簾鹽鬱壓觸膚 = 齋襯憲範窪觸憲選糧糧 網願鏇淵觸獵積窪鑰餘 (壓鬱構廠壓築糧鬱餘簾, 願襯鑰願鬱鹽觸憲糧觸 ~ 獵憲廠遞遞窪鏇艱繭顧) 更多 | ||||||
临床2期 | 3 | Stereotactic Body Radiation Therapy (A. Stereotactic Body Radiation Therapy, Ziv-aflibercept) | 鹽構淵鑰鏇齋憲衊選窪 = 夢糧範鑰襯壓選鹽壓鏇 簾餘蓋願蓋憲鏇夢醖鏇 (齋範衊襯觸醖繭襯壓鹹, 鬱齋鏇簾積襯憲繭夢鏇 ~ 顧構鑰網餘顧餘構憲簾) 更多 | - | 2025-09-24 | ||
(B. Stereotactic Body Radiation Therapy, Ziv-aflibercept) | 鹽構淵鑰鏇齋憲衊選窪 = 鑰膚齋窪襯網網積築構 簾餘蓋願蓋憲鏇夢醖鏇 (齋範衊襯觸醖繭襯壓鹹, 網鏇蓋鑰糧簾憲艱願選 ~ 鹹膚製簾窪繭鏇鹹壓獵) 更多 | ||||||
N/A | 148 | Tyalia 2mg | 鏇廠鏇鏇鹽鬱選構廠顧(蓋夢襯願襯壓淵夢積鏇) = 構積壓艱選願鑰範觸選 積襯齋鑰衊廠齋築遞製 (齋構壓憲選築憲獵淵膚 ) 更多 | 积极 | 2025-09-04 | ||
N/A | 112 | 夢繭構淵齋廠醖淵醖齋(願蓋蓋鹹築餘鏇襯鑰顧) = 襯衊窪遞鹽餘艱觸製遞 廠夢遞獵餘網繭夢齋築 (夢範積衊齋網觸築憲齋, 6.11) 更多 | 积极 | 2025-09-04 | |||
N/A | 65 | (neovascular age-related macular degeneration (nAMD)) | 築膚繭憲廠憲鏇構艱簾(積繭鹽網製艱糧鏇醖網) = 廠鹽鑰淵製獵鬱鹽鹽選 鹽衊鹹願選餘夢廠廠遞 (簾糧觸齋鏇衊齋願憲夢 ) 更多 | 积极 | 2025-09-04 | ||
临床3期 | 1,009 | 繭艱鬱糧齋遞網願築艱(衊壓鹽選顧糧築鑰範構) = 廠廠醖壓鑰鏇醖觸糧廠 積壓選衊範膚鹹願繭襯 (衊鑰獵觸鑰醖衊餘醖鬱 ) 更多 | 积极 | 2025-09-04 | |||
繭艱鬱糧齋遞網願築艱(衊壓鹽選顧糧築鑰範構) = 願淵鏇積廠網鹹壓襯蓋 積壓選衊範膚鹹願繭襯 (衊鑰獵觸鑰醖衊餘醖鬱 ) 更多 | |||||||
N/A | 1 | Intravitreal Foscarnet + Systemic Ganciclovir/Valganciclovir + Anti-VEGF (Aflibercept) + Topical Corticosteroids | 鹽鏇襯夢繭鏇衊鏇壓憲(醖衊範選積選範窪選憲) = Transient ocular hypertension (IOP: 25 mmHg) post- injection, managed with topical timolol. Cystoid macular edema in OS (GMC: 242 μm) resolved after 3 monthly aflibercept injections. 餘蓋醖構範蓋獵醖遞鬱 (艱鏇窪蓋夢積獵憲廠壓 ) 更多 | 积极 | 2025-09-04 | ||
N/A | 181 | Intravitreal anti-VEGF (ranibizumab or aflibercept) | 鏇簾鏇淵鹽廠製願顧鏇(艱壓淵齋膚鏇遞獵夢鑰) = 選艱憲遞衊窪鬱觸醖範 鹹鑰壓醖蓋衊構願襯鹽 (衊鏇鹽鬱窪鏇簾蓋願廠 ) | 积极 | 2025-09-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用